These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

742 related items for PubMed ID: 25870079

  • 21. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
    Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A, RESTORE study group.
    Ophthalmology; 2011 Apr; 118(4):615-25. PubMed ID: 21459215
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema.
    Rayess N, Rahimy E, Ying GS, Bagheri N, Ho AC, Regillo CD, Vander JF, Hsu J.
    Am J Ophthalmol; 2015 Jan; 159(1):85-91.e1-3. PubMed ID: 25261844
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema.
    Nepomuceno AB, Takaki E, Paes de Almeida FP, Peroni R, Cardillo JA, Siqueira RC, Scott IU, Messias A, Jorge R.
    Am J Ophthalmol; 2013 Sep; 156(3):502-510.e2. PubMed ID: 23795985
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effect of macular ischemia on intravitreal ranibizumab treatment for diabetic macular edema.
    Douvali M, Chatziralli IP, Theodossiadis PG, Chatzistefanou KI, Giannakaki E, Rouvas AA.
    Ophthalmologica; 2014 Sep; 232(3):136-43. PubMed ID: 25171753
    [Abstract] [Full Text] [Related]

  • 29. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
    Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, BRAVO Investigators.
    Ophthalmology; 2010 Jun; 117(6):1102-1112.e1. PubMed ID: 20398941
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.
    Augustin AJ, Kuppermann BD, Lanzetta P, Loewenstein A, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group.
    BMC Ophthalmol; 2015 Oct 30; 15():150. PubMed ID: 26519345
    [Abstract] [Full Text] [Related]

  • 32. Anatomical and functional responses in eyes with diabetic macular edema treated with "1 + PRN" ranibizumab: one-year outcomes in population of mainland China.
    Lai K, Huang C, Li L, Gong Y, Xu F, Zhong X, Lu L, Jin C.
    BMC Ophthalmol; 2020 Jun 15; 20(1):229. PubMed ID: 32539744
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.
    Campochiaro PA, Khanani A, Singer M, Patel S, Boyer D, Dugel P, Kherani S, Withers B, Gambino L, Peters K, Brigell M, TIME-2 Study Group.
    Ophthalmology; 2016 Aug 15; 123(8):1722-1730. PubMed ID: 27236272
    [Abstract] [Full Text] [Related]

  • 35. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment.
    Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R, Hafiz G, Campochiaro PA, READ-2 Study Group.
    JAMA Ophthalmol; 2013 Feb 15; 131(2):139-45. PubMed ID: 23544200
    [Abstract] [Full Text] [Related]

  • 36. Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema.
    Moshfeghi AA, Shapiro H, Lemmon LA, Gune S.
    Ophthalmol Retina; 2018 Feb 15; 2(2):86-90. PubMed ID: 31047350
    [Abstract] [Full Text] [Related]

  • 37. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
    Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY, CRUISE Investigators.
    Ophthalmology; 2010 Jun 15; 117(6):1124-1133.e1. PubMed ID: 20381871
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab.
    Ebneter A, Wolf S, Zinkernagel MS.
    Br J Ophthalmol; 2016 Mar 15; 100(3):365-70. PubMed ID: 26187951
    [Abstract] [Full Text] [Related]

  • 40. Association between characteristics of foveal cystoid spaces and short-term responsiveness to ranibizumab for diabetic macular edema.
    Murakami T, Suzuma K, Uji A, Yoshitake S, Dodo Y, Fujimoto M, Yoshitake T, Miwa Y, Yoshimura N.
    Jpn J Ophthalmol; 2018 May 15; 62(3):292-301. PubMed ID: 29460019
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.